NCT04674020招募中4 期
Registry for Migraine - Structural and Functional Magnetic Resonance Imaging Before and After Erenumab Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 250
- 试验地点
- 1
- 主要终点
- Headache Diary
研究概览
简要总结
This study aims to investigate structural and functional cerebral changes using magnetic resonance imaging before and after treatment with erenumab in patients with migraine.
详细描述
Migraine is a prevalent neurological disorder and a leading cause of years lived with disability worldwide. As of recent, therapies targeting calcitonin gene-related peptide (e.g. erenumab) have been approved for the preventive treatment of migraine. This study aims to investigate structural and functional cerebral changes using magnetic resonance imaging before and after treatment with erenumab in patients with migraine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
盲法说明
Open-label
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has provided informed consent prior to initiation of any study-specific activities/procedures
- •Age greater than or equal to 18 years upon entry into screening
- •History of migraine (with or without aura) for greater than or equal to 12 months before screening according to the International Headache Society (IHS) Classification ICHD-3 (Headache Classification Committee of the International Headache Society, 2018) based on medical records and/or patient self report
- •Greater than or equal to 4 headache days that meet criteria as migraine days per month on average across the 3 months before screening after baseline period
- •Must have demonstrated greater than or equal to 75% compliance in headache diary usage during baseline period
排除标准
- •Subjects are excluded from the study if any of the following criteria apply:
- •Disease Related
- •Greater than 50 years of age at migraine onset
- •History of cluster headache or hemiplegic migraine headache
- •Inability to differentiate between migraine from other headaches
- •The subject is at risk of self-harm or harm to others as evidenced by past suicidal behaviour
- •History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion Prior/Concomitant Therapy
- •Previously received erenumab (Aimovig®)
- •Received an anti-CGRP monoclonal antibody within 3 months prior to the start of the baseline period Prior/Concurrent Clinical Study Experience
- •Currently receiving treatment in another investigational device or drug study, or less than 30 days or 5 half-lives since ending treatment on another investigational device or drug study (ies). Other investigational procedures while participating in this study are excluded.
- •Other Exclusions
- •Female subjects of childbearing potential with a positive pregnancy test assessed at screening or day 1 by a urine pregnancy test.
- •Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 16 weeks after the last dose of investigational product.
- •Female subjects of childbearing potential unwilling to use 1 acceptable method of effective contraception during treatment and for an additional 16 weeks after the last dose of investigational product.
- •Evidence of current pregnancy or breastfeeding per subject self-report or medical records
- •Subject has known sensitivity to any of the products or components to be administered during dosing
- •Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge
- •Contraindications to MRI:
- •Does not wish to be informed about unexpected MRI findings
- •Severe claustrophobia
- •Implanted magnetic material including pacemaker, prothesis, metal-clips, etc.
- •Insulin pump which cannot be removed
- •Magnetic foreign object in the body
- •Surgical intervention within 6 weeks prior to MRI
研究组 & 干预措施
Single-Arm
Experimental
Erenumab packed in a SureClick® Autoinjector Pen (AI).
干预措施: Erenumab (Drug)
结局指标
主要结局
Headache Diary
时间窗: Baseline Phase (Day -42 to -28) to Month 6]
Headache diary with daily entries to record migraine-related data.
次要结局
- 3T Brain Structural and Functional Magnetic Resonance Imaging (MRI) at Baseline at Month 6(Week 24 ± 2 Weeks)
- 3T Brain Structural and Functional Magnetic Resonance Imaging (MRI) at Baseline at Month 12(Week 48 ± 4 Weeks)
- Blood Specimen for Analysis of Biomarkers at Month 12(Week 48 ± 4 Weeks)
- Semi-Structured Interview(Baseline Phase (Day -42 to -28))
- Blood Specimen for Analysis of Biomarkers at Month 6(Week 24 ± 2 Weeks)
- 3T Brain Structural and Functional Magnetic Resonance Imaging (MRI) at Baseline(Baseline Phase (Day -42 to -28))
- Headache Diary(Baseline Phase (Day -42 to -28) to Month 12)
- Blood Specimen for Analysis of Biomarkers at Baseline(Baseline Phase (Day -42 to -28))
研究者
Messoud Ashina
Prinicipal Investigator
Danish Headache Center
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Longitudinal Changes of Brain Functional Connectivity in MigraineMigraineNCT03487978Samsung Medical Center100
已完成
不适用
Assessing gray matter volume in patients with idiopathic rapid eye movement sleep behavior disorderIdiopathic rapid eye movement sleep behavior disorderMental and Behavioural DisordersIdiopathic rapid eye movement (REM) sleep behavior disorderISRCTN18238599Huashan Hospital, Fudan University39
已完成
不适用
Changes in migraine pathway - an MRI studyG43.0G43.1Migraine without aura [common migraine]Migraine with aura [classical migraine]DRKS00023764Klinik für Neurologie und Neurophysiologie Uniklinik Freiburg100
已完成
不适用
Structural and Molecular Neuroplasticity in MigraineMigraineNCT03004313University of Michigan32
已完成
不适用
Neurophysiology of Prophylactic Treatment in MigraineMigraineNCT04019496University Medicine Greifswald44